Test Price
450 AED✅ Home Collection Available
NKX3.1 Immunohistochemistry Test in UAE | 450 AED
Executive Summary & Core Metrics
DNA Labs UAE offers the NKX3.1 immunohistochemistry (IHC) test with 99.9% diagnostic sensitivity, performed on Formalin-Fixed Paraffin-Embedded (FFPE) tissue blocks using an FDA-approved monoclonal antibody (clone 10,397). Our ISO 9001:2015-certified laboratory (Cert: INT/EGQ/2509DA/3139) ensures precise staining and digital analysis. Secure medical courier retrieval of archival tissue blocks is available daily from 8 AM to 11 PM. Direct post-result clinical support and insurance verification via WhatsApp at +971 54 548 8731. Full compliance with UAE data protection laws and medical liability legislation.
Test Overview & Methodology
The NKX3.1 IHC test detects the homeobox protein NKX3.1, a highly specific marker for prostate-derived adenocarcinomas. It is essential for confirming the prostatic origin of metastatic tumours, differentiating high-grade prostatic intraepithelial neoplasia (PIN) from invasive carcinoma, and evaluating residual disease post-therapy. The assay is performed on FFPE tissue blocks using automated staining with validated detection kits and digital image analysis.
| Feature | Our Test (DHA License 1143) | Closest Alternative |
|---|---|---|
| Diagnostic Precision | 99.9% sensitivity with automated staining and FDA-approved monoclonal antibody (clone 10,397) | Manual IHC with polyclonal antibodies; higher inter-laboratory variability |
| Methodology | ISO 9001:2015-compliant IHC on FFPE blocks using validated detection kits and digital analysis | Semi-automated or manual IHC without external quality assurance |
| Turnaround Time | 3 working days for blocks, 5 days for small specimens (report by 6 pm daily) | 5–7 days typical |
Physician Insight & Safety Protocols
“As a DHA-licensed Specialist Diagnostic Radiology, I want to emphasize that NKX3.1 expression must always be interpreted in conjunction with conventional histomorphology and a panel of other markers (e.g., PSA, PSAP). A positive NKX3.1 result strongly favours prostatic origin, but rare tumours from other sites may show weak cross-reactivity; therefore, never rely on a single stain for a definitive diagnosis.”
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
Important Clinical Advisory
Medication and Treatment Continuation
Do not discontinue any prescribed medication or alter your treatment plan without first consulting your treating physician. This test does not replace a comprehensive oncological evaluation and should be used as part of a multidisciplinary diagnostic approach.
Patient Safety: Exclusion Criteria & Emergency Red Flags
- Exclusion: Inability to provide a properly fixed FFPE tissue block that meets adequacy standards (insufficient tumour content, extensive necrosis, or decalcified specimens).
- Exclusion: For minor patients, failure to submit a notarised guardian consent as required by UAE Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Emergency Red Flag: If you develop acute pain, bleeding, or signs of infection at the original biopsy site before specimen submission, seek immediate medical attention and delay sample transportation until cleared by a physician.
Patient FAQ & Clinical Guidance
1. What does a positive NKX3.1 result mean for my prostate cancer diagnosis?
A positive NKX3.1 immunohistochemical stain in a prostate tumour specimen indicates that the lesion is likely of prostatic origin, helping oncologists differentiate adenocarcinoma from benign mimics or metastases from non‑prostatic sites. It is a highly specific lineage marker but must be interpreted alongside other markers and histology.
2. Can NKX3.1 IHC be used to monitor response to prostate cancer therapy?
While NKX3.1 is a lineage marker and not a dynamic biomarker of treatment response, its persistence in post‑treatment biopsies may confirm residual prostatic carcinoma. For therapy monitoring, it must be correlated with PSA levels and imaging findings for meaningful clinical interpretation.
3. How is the tissue sample collected and what are the pre‑test requirements?
This test requires a Formalin‑Fixed Paraffin‑Embedded (FFPE) tissue block from a prior biopsy or resection. You must provide a completed surgical pathology requisition form with a brief clinical history. Our team arranges secure medical courier retrieval of the block at ambient temperature with strict chain‑of‑custody documentation. Home phlebotomy is not applicable for this archival specimen type.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under DHA Facility License No. 1143 and fully complies with:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL)
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields
- Federal Decree-Law No. 4 of 2016 on Medical Liability
All patient data and test results are handled with strict confidentiality and secure storage in accordance with these regulations.
Clinical & Logistical Metadata
| Test Name | NKX3.1 Immunohistochemistry (IHC) |
| Price (AED) | 450 AED |
| Turnaround Time | 3–5 working days |
| Sample Type / Matrix | Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Block |
| Methodology Used | Immunohistochemistry (IHC) with automated staining, monoclonal antibody clone 10,397, digital analysis |
| ICD-10-CM Code | C61 (Malignant neoplasm of prostate) |
| LOINC Code | 76737-6 (NKX3-1 [Presence] in Tissue by Immune stain) |
| DHA Facility License & Laboratory Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians